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MacrophagesFumaric acid esters (FAEs) exert therapeutic effects in patients with psoriasis and multiple sclerosis, however
their mode of action remains elusive. Pyroptosis is a caspase-1-dependent pro-inflammatory form of pro-
grammed cell death, mediated by the activation of inflammasomes. To understand the pharmacological basis
of the therapeutic effects of FAEs, the anti-pyroptotic activity of dimethyl fumarate (DMF) and its hydrolysis me-
tabolite monomethyl fumarate (MMF) was studied in a model of NLRP3 inflammasome-mediated pyroptosis of
human macrophages. Phorbol myristate acetate-differentiated THP-1 cells were exposed to lipopolysaccharide
(5 μg/ml; 4 h), then pulsed with ATP (5 mM; 1 h). MMF, DMF, or parthenolide (positive control) were added
1 h before the ATP pulse. The pyroptotic cell death was evaluated by morphological examination and quantified
by measuring the lactate dehydrogenase leakage. The ATP-triggered death of THP-1 cells (60.4 ± 4.0%) was
significantly (P b 0.01) prevented by DMF, in a time- and concentration-dependent manner (pIC50 and maximal
effect were 6.6 and 67.6 ± 1.2%, respectively). MMFwas less efficacious than DMF. These effects were accompa-
nied by a decreased intracellular activation of caspase-1 and interleukin-1β release from ATP-treated cells, thus
suggesting that FAEs antagonise the effects of ATP by preventing the activation of the pyroptotic molecular
cascade leading to cell death. These results indicate that FAEs are endowed with anti-pyroptotic activity, which
may contribute to their therapeutic effects.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The first use in medicine of fumaric acid (FA) derivatives was de-
scribed by Schweckendiek W., who suffered himself from psoriasis. He
raised the hypothesis that disturbances in the Krebs cycle might be im-
plicated in the pathogenesis of this disease, and postulated that exoge-
nous supplementation of FA, which is an intermediate of the Krebs
cycle, might reverse the pathological process. Schweckendiek tried to
prove his hypothesis by treating himself with FA derivatives and report-
ed on the successful treatment in a self-experiment [1]. A role for an ab-
normal metabolism of FA in psoriasis was never proven, nevertheless,
the effectiveness combined with a favourable long-term safety profile
of drug products containing fumaric acid esters (FAEs) has been demon-
strated in several clinical trials [2,3]. In 1994, Fumaderm®, a drug prod-
uct consisting of dimethyl fumarate (DMF), calcium-, magnesium-, and
zinc-salts of monoethyl fumarate, was approved in Germany as an oral
treatment of psoriasis vulgaris. Over the last 15 years, compelling datahloromethylketone; Ac-YVAD-
marate; FA, fumaric acid; FAEs,
H, lactate dehydrogenase; LPS,
orbol myristate acetate; RRMS,
a e Tecnologia del Farmaco,
, Italy.on the effects exerted by FAEs have been accumulated. In particular,
the evidence that BG-12, which in contrast to Fumaderm® consists of
only DMF, exerts therapeutic effects in patients with relapsing–
remittingmultiple sclerosis (RRMS) [4–6] has received a lot of attention.
In 2013, BG-12/Tecfidera® was approved in many countries as an oral
treatment of RRMS. Despite the accumulated data, the mode of action
of FAEs remains a matter of debate.
Pyroptosis is a caspase-1-dependent and pro-inflammatory form of
programmed cell death. It can be triggered in myeloid and non-myeloid
cell types both by bacterial products and non-bacterial stimuli, including
viruses, microparticles, as well as host factors (i.e., misfolded proteins)
[7]. Pyroptosis ismediated by the activation of inflammasomes, and is ac-
companied by release of pro-inflammatory signals, including interleukin
(IL)-1β and ATP [7,8]. To date, several inflammasomes have been identi-
fied, and the NLRP3 inflammasome is the most studied. The activation of
NLRP3 inflammasome is commonly described as a process requiring two
stimuli. Many Toll-like receptor ligands (i.e., lipopolysaccharide, LPS;
priming stimulus) prime cells by inducing the NF-κB-dependent expres-
sion of the NLRP3 protein. A further stimulus (i.e., ATP; activating
stimulus) triggers the formation of the inflammasome complex, that
leads to the activation of caspase-1, and eventually pyroptosis [7,8]. As
pyroptosis is thought to contribute to the pathogenesis of a broad spec-
trum of disease, characterized by excessive/uncontrolled cell death and
inflammation, compounds endowed with anti-pyroptotic activity are of
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unrelated small molecules, including parthenolide and Bay 11-7082 [9],
resatorvid/TAK-242, 5Z-7-oxozeaneol, and bromoxone [10], compound
9 and related derivatives [11] (Fig. S1A) have been shown to prevent
pyroptosis in in vitro experiments. The effects of FAEs on pyroptotic
cell death have never been studied. The aim of this study was to investi-
gate the anti-pyroptotic activity of DMF and its hydrolysis metabolite
monomethyl fumarate (MMF; Fig. S1B) in an in vitro model of NLRP3
inflammasome-mediated and ATP-triggered pyroptosis of human
macrophages.
2. Materials and methods
2.1. Cell cultures
Human myelomonocytic THP-1 cells were cultured in RPMI 1640
medium (purchased from Lonza, Basel, Switzerland), supplemented
with foetal bovine serum (10%; Lonza), L-glutamine (2 mM; Lonza),
penicillin (100 IU/ml; Lonza), and streptomycin (100 mg/ml; Lonza).
Cell culture medium was replaced every 2–3 days, and the cultures
were maintained at 37 °C, 95% air/5% CO2 in a fully humidified incuba-
tor. Theday before each experiment, cellswere plated in 48-well culture
plates (7.5 × 104 or 1.5 × 105 cells/well for the measurement of
pyroptosis and IL-1β release, respectively) and were differentiated
into monocytes/macrophages by treatment with phorbol myristate
acetate (PMA; Sigma-Aldrich, Saint Luis, MO, USA; 50 nM, 24 h).
2.2. An in vitro model of pyroptosis
The effects of DMF and MMF were studied in a model of NLRP3
inflammasome-mediated pyroptosis of human macrophages, as de-
scribed by Gong et al. [10]. Briefly, PMA-differentiated THP-1 cells
were primed with LPS (from Escherichia coli 055:B5; 5 μg/ml; 4 h;
Sigma-Aldrich) in serum-free medium. Pyroptosis was triggered with
ATP (5 mM; 60 min; Sigma-Aldrich). The CytoTox 96 Non-Radioactive
Cytotoxicity Assay kit (Promega Corporation, Madison, MI, USA), a
colorimetric assay based on themeasurement of the lactate dehydroge-
nase (LDH) activity in the collected supernatants, was used to deter-
mine the percentage of cell death, according to the manufacturer's
instruction.
2.3. Measurement of caspase-1 activity
Caspase-1 activity was measured by a spectrophotometric assay as
previously described [11]. Reactions were carried out in 96-well plates
in 100 μl final volume at 37 °C by diluting enzyme (50 U) in the reaction
buffer (100 mM HEPES, 10% sucrose, 0.1% CHAPS, pH 7.5, 10 mM DTT)
and monitoring liberation of the chromophore from a specific labelled
substrate [Ac-Tyr-Val-Ala-Asp-p-nitroaniline (Ac-YVAD-pNA; 200 μM
final concentration); Vinci-Biochem; Vinci, Italy] in a Victor X4
(PerkinElmer, Waltham, MA, USA) at a wavelength of 405 nm. Absor-
bance was monitored at 5-min intervals for 90 min. The caspase-1
inhibitor Ac-Tyr-Val-Ala-Asp-chloromethylketone (Ac-YVAD-CMK;
Vinci-Biochem) was employed as positive control.
2.4. Western blot analyses
Western blot analyses were performed as previously described [10].
Caspase-1 [both the precursor peptide = procasp-1 (45 kDa) and the
p10 subunit] and IL-1β [both the precursor peptide = proIL-1β
(37 kDa) and the mature IL-1β (17 kDa)] were detected with rabbit
polyclonal antibodies (sc-515 and sc-7884, respectively; Santa Cruz
Biotechnology, Dallas, TX, USA). To confirm the homogeneity of the pro-
teins loaded, themembraneswere stripped, and incubatedwith an anti-
β-actin monoclonal antibody (Sigma-Aldrich). The membranes were
overlaid with Western Lightning Chemiluminescence Reagent Plus(PerkinElmer Life Science, Norwalk, CT, USA), and exposed to Hyperfilm
ECL film (Amersham Biosciences, Piscataway, NJ, USA).2.5. IL-1β release
PMA-differentiated THP-1 cells were primedwith LPS (5 μg/ml; 4 h)
and pulsed with ATP (5 mM; 60 min). Supernatants were collected,
centrifuged to discharge cellular debris and assayed for IL-1β by ELISA
(eBioscence, Inc., San Diego, CA, USA).2.6. Statistical and data analysis
Data were fitted and analysed by using the software Origin version
6.0 (Microcal Software, Northampton, MA). Statistical significance was
evaluated by one-way ANOVA followed by the post hoc Bonferroni's
correction; differences were considered statistically significant when
P b 0.05.3. Results
3.1. NLRP3 inflammasome-mediated pyroptosis of differentiated
THP-1 cells
Cells dying by pyroptosis undergo a measurable size increase, cell
swelling and lysis [7]. Morphological changes consistent with the
pyroptotic cell death were observed in PMA- and LPS-treated THP-1
cell cultures exposed to ATP (5 mM; Fig. 1A). Many cells appeared
with marked size increase and underwent lysis. Moreover, compared
to vehicle alone, a significantly higher (60.4± 4.0%; P b 0.01) LDH activ-
ity was measured in the supernatant collected from cell cultures ex-
posed to ATP (5 mM, 60 min), indicating that most cells underwent
lysis after exposure to this recognized pyroptotic stimulus (Fig. 1B).
No significant increase in the LDH activity was instead observed in the
supernatant from cell cultures exposed to either LPS or ATP alone.
These results indicate that differentiated and primed THP-1 cells
pulsed with ATP are a suitable model to study pyroptosis.3.2. Effects of FAEs on the ATP-triggered pyroptosis of differentiated
THP-1 cells
To assess the anti-pyroptotic activity of FAEs, the effects exerted
by MMF and DMF on the NLRP3 inflammasome-mediated and ATP-
triggered pyroptosis were studied and compared to those exerted by
parthenolide, which is endowed with anti-pyroptotic activity [9].
None of these compounds (10 μM, 1 h) inhibited LDH activity (data
not shown), indicating that measurement of this parameter allows to
study their anti-pyroptotic effects.
First, primed THP-1 cells were pre-treated (15–60 min) with either
MMF, DMF, or parthenolide (all at 10 μM), and then pulsed with ATP
(5 mM, 60 min). The ATP-triggered cell death was significantly
prevented (P b 0.05) by these compounds in a time-dependent manner
(Fig. 1C). Compared to MMF, DMF exerted larger effects. As expected,
the nucleotide-triggered cell death was also prevented by parthenolide.
Then, cells were pre-treated (60 min) with increasing concentra-
tions (0.001–10 μM) of MMF, DMF, or parthenolide, and then exposed
to ATP (5 mM, 1 h). The ATP-triggered cell death was prevented by
these compounds in a concentration-dependent manner (Fig. 1D);
pIC50s were 6.6, and 7.2, for DMF and parthenolide, respectively. Both
DMF and MMF were significantly less efficacious than parthenolide
(P b 0.01 for both comparisons), although DMF was significantly more
efficacious than MMF (P b 0.01).
Collectively these results indicate that FAEs are endowed with
anti-pyroptotic activity.
Fig. 1. An in vitromodel of NLRP3 inflammasome-mediated and ATP-triggered pyroptotic cell death and effects of FAEs. PMA-differentiated THP-1 cells were primed with LPS (5 μg/ml;
4 h), then exposed to either vehicle alone or ATP (5 mM, 60 min). (A) Cells exposed to ATP displayed enlarged size and underwent lysis. (B) LDH activity was measured in the collected
supernatants to determine the percentage of cell death. (C) Cells were pre-treated (60–15 min) with MMF, DMF, or parthenolide (all at 10 μM), and then exposed to ATP (5 mM, 1 h).
(D) Cells were pre-treated (60 min) with increasing concentrations (0.001–10 μM) of DMF, MMF, or parthenolide, and then exposed to ATP (5 mM, 1 h). The ATP-triggered cell death
was evaluated by measuring LDH activity in the collected supernatants. Data are the mean ± s.e.m. of six experiments run in triplicate. **P b 0.01 vs vehicle alone; ○○ P b 0.01 for the
indicated comparisons (ANOVA plus Bonferroni's correction).
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To explore themechanism underlying the anti-pyroptotic activity of
FAEs, the effects of MMF, DMF and parthenolide on both caspase-1
activity and caspase-1 intracellular activation were studied. Caspase-1
activity was measured by a cell-free system assay, as previously de-
scribed [11]. As shown in Fig. 2A, caspase-1 activity was significantly
(P b 0.01) inhibited by the caspase-1 inhibitor Ac-YVAD-CMH (positive
control; 100 μM), and parthenolide, but not by DMF and MMF (all at
10 μM). These finding indicate that the anti-pyroptotic activity of FAEs
does not depend on a direct inhibition of caspase-1. By contrast, the
ATP (5mM; 1 h)-triggered caspase-1 intracellular activation in differen-
tiated and LPS-primed THP-1 was prevented by MMF, DMF, and
parthenolide (all at 10 μM; added 1 h before the ATP pulse; Fig. 2B).
To confirm this finding, the release of IL-1β in the extracellular space
was evaluated as a marker of intracellular caspase-1 activation. Com-
pared to cell cultures exposed to vehicle alone, a significantly higher
cytokine level was measured in the supernatant collected from the
primed cultures exposed to ATP (5 mM, 60 min; 10.4 ± 29.7 vs
752.8 ± 111.4 pg/ml, respectively; P b 0.01). As shown in Fig. 2C, the
ATP-triggered IL-1β release was significantly (P b 0.05) and in a
concentration-dependent manner prevented by MMF, DMF, and
parthenolide (0.01–10 μM; added 1 h before the ATP pulse): pIC50s
were 5.8, and 6.8 for DMF and parthenolide, respectively. Both DMF
and MMF were significantly less efficacious than parthenolide(P b 0.01 for both comparisons), although DMF was significantly more
efficacious than MMF (P b 0.01). Of note, comparable levels of proIL-
1β and mature IL-1βwere measured in extracts prepared from primed
cells exposed toMMF, DMF, and parthenolide (all at 10 μM; 1 h; Fig. 2D),
thus indicating that the effects of these compounds on the extracellular
IL-1β level were due to the prevention of the ATP-triggered, caspase-1-
mediated IL-1β processing, instead of IL-1β expression.
Collectively these results indicate that FAEs exert anti-pyroptotic
effects by preventing the intracellular caspase-1 activation.
4. Discussion
Compounds endowed with anti-pyroptotic activity may be novel
agents to counteract disorders characterized by excessive/uncontrolled
cell death and inflammation [8]. In addition, evaluation of the anti-
pyroptotic actions of drugs may be helpful to better understand their
therapeutic effects. In this study the first evidence on the anti-
pyroptotic activity of FAEs is provided. The effects of DMF and MMF
have been evaluated in a well-established cellular model to study the
NLRP3 inflammasome-mediated pyroptosis of human macrophages
[10]. In our experiments, the ATP-triggered death of LPS-primed and
PMA-differentiated THP-1 cells was prevented by DMF and MMF
when theywere added just before ATP, used to trigger cell death.More-
over, it was accompanied by a decreased intracellular activation of
caspase-1. Thereby, FAEs antagonise the effects of ATP by preventing
Fig. 2. Effects of FAEs on caspase-1 activation and IL-1β release. (A) Caspase-1 (50 U) from THP-1 lysates was incubated at 37 °C in the presence of either vehicle alone (DMSO 0.1%), Ac-
YVAD-CMK (positive control, 100 μM), MMF, DMF, or parthenolide (Part; all at 10 μM) for 90min. Caspase-1 activity was measured bymonitoring (at 405 nm) liberation of the chromo-
phore from the labelled substrate Ac-YVAD-pNA. (B) Differentiated and primed THP-1 cells were pre-treated with either vehicle alone (DMSO 0.1%), MMF, DMF, or parthenolide (all at
10 μM; 60 min), and then exposed to ATP (5 mM, 1 h). Caspase-1 activation was evaluated by detecting the precursor (procasp-1; 47 kDa) and the cleaved subunit p10 by western
blot analysis. (C) Differentiated and LPS (5 μg/ml; 4 h)-primed THP-1 cells were pre-treated (60 min) with either vehicle alone (DMSO 0.1%) or increasing concentrations (0.01–
10 μM) of MMF, DMF, or parthenolide, and then exposed to ATP (5 mM, 1 h). IL-1β release was evaluated by measuring the cytokine concentration in the collected supernatants by
ELISA. (D) THP-1 cells were pre-treated (60 min) with either vehicle alone (DMSO 0.1%), MMF, DMF, or parthenolide (all at 10 μM) and the intracellular level of both proIL-1β
(31 kDa) and mature IL-1β (17 kDa) were evaluated by western blot analysis. Data are the mean ± s.e.m. of three experiments run in triplicate. **P b 0.01 vs vehicle alone; ○○
P b 0.01 for the indicated comparisons (ANOVA plus Bonferroni's correction). Images are representative of three experiments.
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icking (at least in part) the effects of not only parthenolide, but also Bay
11-7082 [9], resatorvid, 5Z-7-oxozeaneol, and bromoxone [10], com-
pound 9 and related derivatives [11]. FAEs exerted anti-pyroptotic ef-
fects at low micromolar concentrations. Moreover, DMF was more
efficacious than MMF in preventing the ATP-triggered pyroptotic cell
death as well as IL-1β release from primed THP-1 cells. Differences in
the physicochemical properties (i.e., lipophilia) between these twomol-
ecules could explain, at least in part, this profile. In addition, a different
reactivity toward biological thiols could also contribute to it. The adduc-
tion of DMF and MMF to the free thiol group of glutathione (GSH) [12]
and in the side chain of certain cysteine residues in proteins [13] has
been demonstrated, and it has been shown that DMF is more reactive
thanMMF toward these functional groups. Interestingly, albeit structur-
ally unrelated, most of the anti-pyroptotic compounds so far identified
have electrophilic substructures (Fig. S1A), and Michael-like reactions
with free thiol groups in proteins of the pyroptotic cascades have been
postulated to underlie their activity [9–11]. FAEs even are Michaelacceptors (Fig. S1B), and the adduction to biological targets (i.e., GSH,
Keap-1) has been already suggested to mediate their effects [14–16].
Thereby, in keeping with previous findings, the adduction to proteins
of the pyroptotic cascade could mediate the anti-pyroptotic effects
of FAEs. Our preliminary findings on the reactivity of cysteine resi-
dues in proteins of the pyroptotic cascade toward FA support this
hypothesis [17].
DMF has been demonstrated to be an essential component of
Fumaderm® [18]. Results on BG-12/Tecfidera® are consistent with
this data [4–6]. However, pharmacokinetic studies have shown that
DMF undergoes to a large pre-systemic conversion to MMF and adduc-
tion to GSH [19]. Many in vitro data, including our results, indicate that
compared to MMF, DMF is significantly more efficacious. This evidence
suggests that the therapeutic effects of orally administered DMF could
be related to its actions on the gut-intrinsic mechanisms involved in
the regulation of the immune response. For example, previous studies
[15,16] have shown that DMF inhibits the production by dendritic
cells of pro-inflammatory cytokines (i.e., IL-6, IL-12, and IL-23) involved
219G. Miglio et al. / International Immunopharmacology 28 (2015) 215–219in the differentiation of T helper 17 cells, which preferentially accumu-
late in the intestine [20]. Therefore, by altering the local humoralmilieu,
DMF could affect the differentiation of T helper 17 cell. Our data support
this hypothesis. Indeed, as cells undergoing pyroptosis release IL-1β and
ATP [7,8], which are involved in the T helper 17 cell differentiation
process [20], we would propose that by preventing the NLRP3
inflammasome-dependent pyroptosis of intestinal myeloid cells, orally
administered FAEs may exert beneficial effects by interfering with a
gut-intrinsicmechanism implicated in the pathogenesis of autoimmune
disease, including psoriasis and multiple sclerosis [20]. This hypothesis
needs further investigation.
In conclusion, the anti-pyroptotic compounds are an emergent class
of drugs; our findings indicate that FAEs belong to this class. Together
with previous data our results might contribute to unveil the enigmatic
pharmacological basis behind the therapeutic effects of FAEs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.intimp.2015.06.011.
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